Definitive Healthcare (NASDAQ:DH) Posts Earnings Results

Definitive Healthcare (NASDAQ:DH) released its earnings results on Thursday. The company reported $0.06 EPS for the quarter, meeting the consensus estimate of $0.06, FiscalAI reports. Definitive Healthcare had a positive return on equity of 3.30% and a negative net margin of 77.88%.The company had revenue of $61.53 million during the quarter, compared to analysts’ expectations of $59.57 million. Definitive Healthcare updated its FY 2026 guidance to 0.140-0.170 EPS and its Q1 2026 guidance to 0.030-0.030 EPS.

Here are the key takeaways from Definitive Healthcare’s conference call:

• Definitive reported Q4 results that were at or above the high end of guidance with $61.5M revenue (down 1% YoY) and $18.1M adjusted EBITDA (29% margin), and generated about $55M of unlevered free cash flow on a trailing 12‑month basis.
• The company says it has remediated the claims data disruption—bringing claims volumes back to above historical levels—and expanded core data assets (including added mobile phone data) to strengthen its proprietary dataset.
• Integration and product work accelerated in 2025 (new connectors with Snowflake, Databricks, HubSpot and a PhysicianView/Salesforce pilot), shortening integration time by ~25% and adding over 60 integrated customers in Q4 to improve stickiness.
• Retention trends are mixed: gross dollar retention improved ~2 points YoY and renewal rates rose modestly in recent quarters, but net dollar retention declined due to weak upsell activity; management expects NDR to bottom in 2025 and to modestly recover in 2026.
• 2026 guidance assumes continued top‑line pressure with full‑year revenue of $220M–$226M (down 6%–9% YoY) even as management plans targeted R&D and go‑to‑market investments while preserving a 24%–26% adjusted EBITDA margin.

Definitive Healthcare Price Performance

Shares of DH stock traded down $0.01 during midday trading on Thursday, reaching $1.40. 753,013 shares of the company were exchanged, compared to its average volume of 372,979. The company’s 50 day moving average price is $2.23 and its two-hundred day moving average price is $2.90. The company has a market cap of $197.91 million, a P/E ratio of -0.84 and a beta of 1.59. Definitive Healthcare has a 12 month low of $1.36 and a 12 month high of $5.22. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.60 and a current ratio of 1.60.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Raymond James Financial Inc. bought a new position in shares of Definitive Healthcare in the second quarter valued at $32,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of Definitive Healthcare during the 4th quarter worth $35,000. Bayesian Capital Management LP acquired a new position in shares of Definitive Healthcare in the 2nd quarter worth $55,000. Prelude Capital Management LLC acquired a new stake in shares of Definitive Healthcare during the third quarter worth $64,000. Finally, ExodusPoint Capital Management LP acquired a new stake in shares of Definitive Healthcare during the fourth quarter worth $47,000. Institutional investors own 98.67% of the company’s stock.

Analysts Set New Price Targets

DH has been the topic of a number of recent analyst reports. William Blair upgraded shares of Definitive Healthcare to a “strong-buy” rating in a research note on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Definitive Healthcare in a research note on Wednesday, January 21st. Morgan Stanley reaffirmed an “underperform” rating and set a $3.50 target price on shares of Definitive Healthcare in a report on Thursday, December 18th. Canaccord Genuity Group lowered their price target on Definitive Healthcare from $5.00 to $4.00 and set a “hold” rating for the company in a report on Monday, November 10th. Finally, Barclays dropped their price target on Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating on the stock in a research report on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, Definitive Healthcare currently has a consensus rating of “Hold” and a consensus price target of $3.94.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.